Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | PRKX | P51817 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.39 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24458554 | 0.78 | NR1H2 (0.33) | PARP1PIM1NR1H2PIM3PDPK1 | |
| SCHEMBL2445832 | 0.78 | NR1H2 (0.39) | PARP1PIM1FLT1RPS6KA3NR1H2 | |
| SCHEMBL4812860 | 0.74 | NR1H2 (0.42) | CLK2CLK4CDK7CDK9NR1H2 | |
| SCHEMBL18703973 | 0.68 | KMT2A (0.33) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL16646776 | 0.66 | NR1H2 (0.66) | ALKNR1H2MEN1KMT2AALDH1A1 | |
| SCHEMBL170132 | 0.65 | ACVR1 (0.43) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL13177408 | 0.65 | KMT2A (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL12406064 | 0.63 | PARP1 (0.35) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL2456941 | 0.63 | NR1H2 (0.42) | PARP1DAPK3PRKD3PIM1GSK3A | |
| SCHEMBL18956248 | 0.63 | NR1H2 (0.36) | PARP1PIM1NR1H2PIM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230129944-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230129944-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20210284645-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2021-09-16 | — | — | US | disclosed |
| US-10807985-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190144454-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2019-05-16 | — | — | US | disclosed |
| EP-3057969-B1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORP (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9994575-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-9944651-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-20050288289-A1 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | PARP1 1441/4885AURKA 112/4885DAPK3 134/4885 |
| US-10807985-B2 | Compositions useful for treating disorders related to kit | KIT, APC, MSH2 | PARP1 2842/4885AURKA 2954/4885DAPK3 3834/4885 |
| US-20050288289-A1 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | MAP3K15, MAP4K2, MAP3K20 | PARP1 774/4885AURKA 92/4885DAPK3 161/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | PARP1 1523/4885AURKA 244/4885DAPK3 123/4885 |
| US-20190144454-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | PARP1 2842/4885AURKA 2954/4885DAPK3 3834/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | PARP1 1441/4885AURKA 112/4885DAPK3 134/4885 |
| US-11827642-B2 | Compositions useful for treating disorders related to KIT | KIT, APC, MSH2 | PARP1 2842/4885AURKA 2954/4885DAPK3 3834/4885 |
| US-20210284645-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | PARP1 2842/4885AURKA 2954/4885DAPK3 3834/4885 |
| US-20070123534-A1 | Pyrrolotriazine kinase inhibitors | MAP3K15, MAP3K5, STK25 | PARP1 1481/4885AURKA 205/4885DAPK3 110/4885 |
| US-20230129944-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | PARP1 2842/4885AURKA 2954/4885DAPK3 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.